AMES, Iowa—Clinical trials researching treatments and preventative measures for COVID-19 are
underway at McFarland Clinic.
The COVID-19 clinical trials are being conducted by PMG Research of McFarland Clinic. PMG Research
Inc. is a global integrated network of clinical research facilities, conducting clinical trials since 1979. Their
research facility is staffed by an experienced team in a variety of specialties including allergy, cardiology,
dermatology, neurology, obstetrics and gynecology, and oncology.
“We partner with value-based healthcare institutions and multi-specialty practices that also see the value
of clinical research and the benefit of offering it as a care option to the patients for whom they serve,”
PMG Research Manager of Clinical Operations Erin Hackett said.
McFarland Clinic Adult Medicine Physician Jennifer Killion, MD is a principal investigator in these
COVID-19 clinical trials. In her role, Dr. Killion is responsible for making sure that protocols are followed,
monitoring of patient safety, and signing off on all of the delegation. Dr. Killion was involved in a 2019
pneumonia vaccine trial before the COVID trials began.
McFarland Clinic Neurologist and Director of Research David Moore, MD, helps to oversee clinical trials
from the clinical perspective. PMG finds studies that the clinic and providers are interested in doing, and
puts together teams to begin facilitating the studies. When COVID began spreading in Iowa, Dr. Moore
said that no one expected the shift in these studies to happen so quickly, especially with an infectious
disease that was quickly changing.
“There have been viruses that have been out there that are Coronaviruses. At the time we were made
aware of COVID-19, no one ever thought it would be like this, like a rapidly affecting virus because it is
spread by air and not by touch,” Dr. Moore said.
For more information and the full story, visit mcfarlandclinic.com/trials. If you are interested in enrolling in
clinical trials with McFarland Clinic and PMG Research, call 515-956-4159.
(contributed press release)
About the Author
